Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
about
NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancerAn intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situUnderstanding and treating triple-negative breast cancerAfrican ancestry and higher prevalence of triple-negative breast cancer: findings from an international studyRisk factors for triple-negative breast cancer in women under the age of 45 yearsMesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancersCancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesApproach to the Triple Negative Breast Cancer in New Drugs AreaA Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerBiomarkers in triple negative breast cancer: A reviewExploring miRNA-Associated Signatures with Diagnostic Relevance in Glioblastoma Multiforme and Breast Cancer PatientsA Quantitative Perspective on Surface Marker Selection for the Isolation of Functional Tumor CellsImplications of the Hybrid Epithelial/Mesenchymal Phenotype in MetastasisMolecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancersEpithelial-mesenchymal plasticity in carcinoma metastasisSLUG: Critical regulator of epithelial cell identity in breast development and cancerNon-Specific Blocking of miR-17-5p Guide Strand in Triple Negative Breast Cancer Cells by Amplifying Passenger Strand ActivityThe clinical and functional significance of c-Met in breast cancer: a reviewThe LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancerGene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB familyDistinct effects of EGFR ligands on human mammary epithelial cell differentiationMicroRNA-223 Increases the Sensitivity of Triple-Negative Breast Cancer Stem Cells to TRAIL-Induced Apoptosis by Targeting HAX-1Nuclear Kaiso expression is associated with high grade and triple-negative invasive breast cancerAn embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumorsBreast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.The differences in ultrasound and clinicopathological features between basal-like and normal-like subtypes of triple negative breast cancer.Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies.Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.Live multicellular tumor spheroid models for high-content imaging and screening in cancer drug discovery.Application of visualization tools to the analysis of histopathological data enhances biological insight and interpretation.Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.The molecular portraits of breast tumors are conserved across microarray platforms.Nectin-4 is a new histological and serological tumor associated marker for breast cancer.Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherinMolecular characterization of human breast tumor vascular cells.The transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesisThe clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.A compact VEGF signature associated with distant metastases and poor outcomes.Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trialMolecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
P2860
Q21560948-CB3E088A-1EEA-4FC4-8A8D-04D63B72BDB5Q22000769-9D04E9A2-7EAD-4101-9B4C-392B1988F7CEQ24620957-BCE9F136-CD95-481B-B2C5-3E1A0C654964Q24632274-DF9F19D8-7639-4B5E-9611-879EC1C4143DQ24644075-B842BC2A-C8E7-4633-890C-5F5ABC33C9E0Q24674085-4AE4FDC3-5D27-4944-A3E3-E544C447F697Q26743510-0E16FDE8-856D-4AC0-B75E-47B56137BA0CQ26744054-2A69D6D8-0D8A-4E53-A9CF-AFBDF2FC33E3Q26752846-289D1489-7BE0-4642-8E9F-4AF0EFA5D47DQ26775094-608705A7-D273-4F18-8AA4-88B522CF7ABFQ26796590-5A68BC80-7D73-4B10-A5A3-0147BB1D0F34Q26797232-3DEDBF97-EAFD-4402-905A-60546F3233E0Q26799987-1D7AC80E-8858-4FBC-BC70-10130CA7A9BCQ26822406-98CD2660-AD6D-4EAA-A5A9-FD29A6678384Q26859804-0B521352-A019-4146-81D3-52F925625EFFQ26865846-9585572D-F641-49F0-B45E-32CC8CC90FB8Q27345210-BFA70092-9BF7-451E-8A3F-6764A5411E4EQ28081415-F37AE6DC-87BC-4706-B67E-62BD7FD7DC1BQ28118941-564A44E2-3847-4C5A-99E0-58B78709F619Q28258227-82813DA1-2931-4997-A8CE-287526C50160Q28534115-93F0A2D1-A320-405D-8A2D-C880DB5F7518Q28554012-3B4FA376-E00D-4D1D-84A1-3142554AA930Q28729209-F534934F-BD88-4B98-9D52-D3F352DDCF8AQ29615393-9606EA74-D8A9-455B-9696-A574D6A6ADE4Q30245184-9B9C78F0-8ADF-4CD5-A02A-2F4D80ECA704Q30417120-19D0AAF5-CD3E-47F1-B747-22423D248715Q30447049-EF3A3F64-C903-40C0-B296-C439E50C1E2BQ30491493-95D4685A-1884-4C26-A51E-F221A69A67C6Q30573300-166483B6-86D0-4F82-84CA-275AE2EE39BDQ31086776-BB4D312C-02A3-4C04-8935-957AB92F92B5Q31153510-DF065454-2412-447F-8715-30DECF618FE2Q33241398-D3ABAC7F-6717-4CAF-BCC5-9D3E2EC98EA2Q33283461-7912A850-7D47-4B65-A53B-B415D26996E3Q33317058-79EC6E21-2C97-4E31-B0EB-8C84D749F58FQ33327647-5FF2AB33-67E3-475A-86CC-D203FF6C153BQ33371124-F84E4FBE-A5F3-4570-BCE6-8685D657DC73Q33378965-09FCD53B-DF43-43F5-AB6E-056567BF756BQ33418745-501956C4-4BCD-4C2D-951D-1D23B79F8739Q33434092-AB0DAAF1-5956-48F2-804A-72944928BBF8Q33479152-74272C3B-7695-4180-A0C8-9F95444B71DE
P2860
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
@ast
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
@en
type
label
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
@ast
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
@en
prefLabel
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
@ast
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
@en
P2093
P2860
P1433
P1476
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
@en
P2093
Chad A Livasy
Dominic T Moore
Gamze Karaca
Maria S Tretiakova
Rita Nanda
P2860
P2888
P304
P356
10.1038/MODPATHOL.3800528
P577
2006-02-01T00:00:00Z
P5875
P6179
1018899345